Pharmafile Logo
Pharmafocus logo
Advanced Search

ViiV Healthcare

Showing 10 posts of 25 posts found.

landing-hero-images1

ViiV’s two-drug regimen gets EU approval for HIV-1

May 22, 2018
Manufacturing and Production, Sales and Marketing EMA, EU, Europe, HIV, Juluca, ViiV Healthcare, pharma

ViiV Healthcare has announced that its HIV therapy Juluca (dolutegravir/rilpivirine) has been awarded marketing authorisation in the EU from the …

News
gilead-sciences

FDA approves Gilead’s Biktarvy for HIV as Viiv Healthcare launches patent lawsuit

February 8, 2018
Sales and Marketing Biktarvy, FDA, GSK, Gilead, HIV, Pfizer, Shionogi, US, ViiV Healthcare, descovy, pharma

Gilead has announced that its daily single-tablet therapy Biktarvy has received FDA approval for HIV-1 infection.

News
gsk_boronia_australia

FDA approves first-ever two-drug HIV regimen, GSK’s Juluca

November 22, 2017
Research and Development, Sales and Marketing AIDS, FDA, GSK, Gilead, GlaxoSmithKilne, HIV, Juluca, ViiV Healthcare, pharma

GlaxoSmithKline has announced that the FDA has awarded US marketing authorisation to the first two-drug regimen in the treatment of …

News

Monthly injectable HIV treatment proves as effective as traditional daily pill regimen

July 24, 2017
Research and Development, Sales and Marketing AIDS, HIV, Janssen, ViiV Healthcare, biotech, drugs, pharma, pharmaceuticals

New early trial data suggests that current daily HIV pill regimens could be replaced with injections which slowly release medication …

News
landing-hero-images1

ViiV Healthcare launches Phase III trial for combo HIV treatment

August 16, 2016
Research and Development Dolutegravir, HIV, Tivicay, ViiV Healthcare, epivir, lamivudine, phase III

The Pfizer/GSK spin off ViiV Healthcare has announced the beginning of a Phase III evaluating Tivicay (dolutegravir) and Epivir (lamivudine) …

News
triumeq-image-pill-bottle

New data shows superior viral suppression for Triumeq in women with HIV

July 18, 2016
Manufacturing and Production, Research and Development Triumeq, ViiV Healthcare

ViiV Healthcare has presented late-stage data showing superior efficacy for combination treatment Triumeq (dolutegravir/abacavir/lamivudine) compared with atazanavir, plus other treatments, …

News
HIV infected cell

ViiV and Janssen to test new HIV regimen in Phase III trial

January 7, 2016
Manufacturing and Production, Medical Communications, Research and Development Edurant, HIV, Janssen, ViiV Healthcare, cabotegravir, collaboration, phase III, rilpivirine

Janssen has formalised its collaboration with ViiV Healthcare on the Phase III development and commercialisation of a two-drug regimen to …

News
landing-hero-images1

ViiV Healthcare to acquire Bristol-Myers Squibb’s HIV pipeline drugs

December 18, 2015
Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, HIV, ViiV, ViiV Healthcare

Specialist HIV company ViiV Healthcare has agreed deals worth up to $1.46 billion to purchase Bristol-Myers Squibb’s late stage HIV …

News
Pharma image

Pharma’s reputation ‘is worsening among patients’

February 10, 2015
Medical Communications, Research and Development, Sales and Marketing HIV, ViiV Healthcare, patientview, pharma, reputation, transparency

Only around four in ten patients believe pharma has a good reputation and many companies are failing to win patient …

News
viiv_gsk_pfizer_david_redfern

David Redfern appointed ViiV chairman

February 28, 2011
Research and Development, Sales and Marketing David Redfern, GSK, GlaxoSmithKline, Pfizer, ViiV, ViiV Healthcare, appointment, research and development, sales and marketing

David Redfern has been appointed as chairman of ViiV Healthcare, the joint GlaxoSmithKline-Pfizer venture focused on HIV.

Appointment
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026